Logo image of XERS

XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Fundamental Analysis

NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD

4.31  +0.03 (+0.7%)

After market: 4.2008 -0.11 (-2.53%)

Fundamental Rating

2

Overall XERS gets a fundamental rating of 2 out of 10. We evaluated XERS against 198 industry peers in the Pharmaceuticals industry. XERS may be in some trouble as it scores bad on both profitability and health. XERS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XERS has reported negative net income.
In the past year XERS has reported a negative cash flow from operations.
In the past 5 years XERS always reported negative net income.
In the past 5 years XERS always reported negative operating cash flow.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

XERS has a Return On Assets of -16.97%. This is in the better half of the industry: XERS outperforms 64.65% of its industry peers.
Industry RankSector Rank
ROA -16.97%
ROE N/A
ROIC N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Gross Margin of XERS (81.86%) is better than 86.36% of its industry peers.
XERS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for XERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
XERS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XERS has more shares outstanding
Compared to 1 year ago, XERS has a worse debt to assets ratio.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

XERS has an Altman-Z score of -1.26. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
XERS's Altman-Z score of -1.26 is in line compared to the rest of the industry. XERS outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.26
ROIC/WACCN/A
WACC10.7%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.67 indicates that XERS should not have too much problems paying its short term obligations.
The Current ratio of XERS (1.67) is worse than 66.67% of its industry peers.
XERS has a Quick Ratio of 1.19. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XERS (1.19) is worse than 71.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.19
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.56%, which is quite good.
XERS shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.88%.
The Revenue has been growing by 137.28% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)23.88%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%35.39%

3.2 Future

XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.91% yearly.
The Revenue is expected to grow by 19.45% on average over the next years. This is quite good.
EPS Next Y78.97%
EPS Next 2Y50.76%
EPS Next 3Y43.6%
EPS Next 5Y34.91%
Revenue Next Year30.46%
Revenue Next 2Y25.69%
Revenue Next 3Y22.88%
Revenue Next 5Y19.45%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

XERS's earnings are expected to grow with 43.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.76%
EPS Next 3Y43.6%

More info and screens

0

5. Dividend

5.1 Amount

XERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (4/25/2025, 8:00:01 PM)

After market: 4.2008 -0.11 (-2.53%)

4.31

+0.03 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners43.73%
Inst Owner Change0.03%
Ins Owners3.43%
Ins Owner Change3.83%
Market Cap663.48M
Analysts85
Price Target6.38 (48.03%)
Short Float %11.73%
Short Ratio5.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.87%
Min EPS beat(2)-19.83%
Max EPS beat(2)53.56%
EPS beat(4)2
Avg EPS beat(4)6.04%
Min EPS beat(4)-19.83%
Max EPS beat(4)53.56%
EPS beat(8)4
Avg EPS beat(8)8.77%
EPS beat(12)8
Avg EPS beat(12)11.28%
EPS beat(16)9
Avg EPS beat(16)2.71%
Revenue beat(2)2
Avg Revenue beat(2)2.42%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3.44%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)3.44%
Revenue beat(8)6
Avg Revenue beat(8)3.87%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)2.08%
PT rev (1m)22.55%
PT rev (3m)31.12%
EPS NQ rev (1m)-6.66%
EPS NQ rev (3m)28.89%
EPS NY rev (1m)63.28%
EPS NY rev (3m)65.44%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)7.35%
Revenue NY rev (1m)9.36%
Revenue NY rev (3m)10.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS1.32
BVpS-0.19
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.86%
FCFM N/A
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.19%
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.19
Altman-Z -1.26
F-Score5
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)9.93%
Cap/Depr(5y)22.72%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y78.97%
EPS Next 2Y50.76%
EPS Next 3Y43.6%
EPS Next 5Y34.91%
Revenue 1Y (TTM)23.88%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%35.39%
Revenue Next Year30.46%
Revenue Next 2Y25.69%
Revenue Next 3Y22.88%
Revenue Next 5Y19.45%
EBIT growth 1Y23.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year183.62%
EBIT Next 3Y69.48%
EBIT Next 5Y46.27%
FCF growth 1Y23.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.36%
OCF growth 3YN/A
OCF growth 5YN/A